The Efficacy of Platelets Rich Plasma for Ovarian Rejuvenation

Infertility, Female Clinical Trial

Official title:

The Efficacy of Platelets Rich Plasma (PRP) for Ovarian Rejuvenation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03946813
• Other study ID #: 12 Al-KindyCM
• Status: Completed
• Phase: N/A
• Start date: August 20, 2018
• Est. completion date: May 31, 2019

Study information

• Verified date: October 2019
• Source: Al-Kindy College of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In recent years, an increased approach has appeared in the use of autologous blood products to assist tissue and organ healing. Application of platelet rich plasma (PRP) has emerged as a potential solution for infertile women with poor ovarian reserve in reproductive specialty.

Description:

Quantitative and qualitative functional improvement of ovarian function has been reported in several studies after using autologous PRP in a reproductive field. Ovarian rejuvenation, stimulating the ovaries to produce new eggs after injecting PRP, can offer hope for renewed fertility to women with poor reserve volume, advanced maternal age, or either naturally occurring or premature menopause. But, these encouraging results should be supported by several new studies.

This study aimed to estimate the efficacy of trans-vaginal ovarian injection with PRP in rejuvenates ovaries in woman with poor ovarian reserve, and to assess any association of some women variables (age, menstrual status, parity, BMI) as predicting factors in success of ovarian injection with PRP.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: May 31, 2019
• Est. primary completion date: May 31, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years to 49 Years

Eligibility

Inclusion Criteria:

1. Menopause or peri-menopause under the age of 50.

2. Premature ovarian insufficiency which is ovarian failure before the age of 40.

3. Woman with primary ovarian failure of any cause.

Exclusion Criteria:

1. A previous injection with any medication, plasma, or PRP

2. Invisible or difficult access ovaries.

3. Medical disease or unfit for anesthesia patient.

Related Conditions & MeSH terms

• Infertility
• Infertility, Female

Intervention

Other:
• Autologous PRP preparation
For each patient, autologous PRP preparation havs to be injected to both ovaries and ultrasound (US) guide

Locations

Country	Name	City	State
Iraq	High Institute for Infertility Diagnosis and Assisted Reproductive Technologies	Baghdad

Sponsors (2)

Lead Sponsor	Collaborator
Al-Kindy College of Medicine	High Institute for Infertility Diagnosis and Assisted Reproductive Technologies

Country where clinical trial is conducted

Iraq, 

References & Publications (1)

A

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Follicle-stimulating hormone (FSH) concentration	Before after intervention measurement	4 weeks
Primary	Anti-Müllerian hormone (AMH) concentration	Before after intervention measurement	4 weeks
Primary	Antral follicles numbers	Before after intervention measurement	4 weeks